Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zanidatamab by Jazz Pharmaceuticals for Breast Cancer: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Breast Cancer. According to GlobalData, Phase...
Zanidatamab by Jazz Pharmaceuticals for Metastatic Biliary Tract Cancer: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Pre-Registration for Metastatic Biliary Tract Cancer. According to GlobalData,...
Zanidatamab by Jazz Pharmaceuticals for Extrahepatic Bile Duct Cancer: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase III for Extrahepatic Bile Duct Cancer. According to...
Zanidatamab by Jazz Pharmaceuticals for Gallbladder Cancer: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase III for Gallbladder Cancer. According to GlobalData, Phase...
Zanidatamab by Jazz Pharmaceuticals for Bladder Cancer: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...
Zanidatamab by Jazz Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
Zanidatamab by Jazz Pharmaceuticals for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According...
Risk adjusted net present value: What is the current valuation of Jazz Pharmaceuticals's Zanidatamab?
Zanidatamab is a monoclonal antibody commercialized by Jazz Pharmaceuticals, with a leading Pre-Registration program in Metastatic Biliary Tract Cancer. According...